2015 Revenue: $932 million (€852.6 million)
HQ: Carros, France
Privately held Virbac got a big boost in 2015 when it acquired the parasiticide for dogs, Sentinel, from Eli Lilly ($LLY)--a product that helped drive its sales up 10% for the year. It was a bright spot in an otherwise difficult year, which started when an FDA inspection forced the company to suspend operations at a St. Louis manufacturing plant. The company’s sales also slowed in South America and France, and unfavorable currency rates sapped the bottom line. But Virbac’s business is growing at double-digit rates in India and growing strongly in China’s companion animal arena. And the company is optimistic about a turnaround in the U.S.--so much so that in March 2016, it announced a $37.9 million expansion in Missouri that will include hiring 144 personnel.
Virbac plans $37.9M expansion in MO, adding 144 animal health jobs
Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal
Nexvet partners with Virbac for ex-U.S. sales of canine osteoarthritis drug